1387 THE NEED FOR CONTINUAL MEDICATION FOR PERSISTENT LOWER URINARY TRACT SYMPTOM AFTER TRANSURETHRAL RESECTION OF THE PROSTATE IS PREDICTED BY THE RESECTED PROSTATE WEIGHT - A NATION-WIDE STUDY

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperlasia: Medical and Hormonal Therapy1 Apr 20131387 THE NEED FOR CONTINUAL MEDICATION FOR PERSISTENT LOWER URINARY TRACT SYMPTOM AFTER TRANSURETHRAL RESECTION OF THE PROSTATE IS PREDICTED BY THE RESECTED PROSTATE WEIGHT - A NATION-WIDE STUDY Chih Chieh Lin, Alex Tong Long Lin, Hsiao Jen Chung, Eric Yi Hsiu Huang, Kuang Kuo Chen, and Tzeng Zi Chen Chih Chieh LinChih Chieh Lin Taipei, Taiwan More articles by this author , Alex Tong Long LinAlex Tong Long Lin Taipei, Taiwan More articles by this author , Hsiao Jen ChungHsiao Jen Chung Taipei, Taiwan More articles by this author , Eric Yi Hsiu HuangEric Yi Hsiu Huang Taipei, Taiwan More articles by this author , Kuang Kuo ChenKuang Kuo Chen Taipei, Taiwan More articles by this author , and Tzeng Zi ChenTzeng Zi Chen Taipei, Taiwan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2741AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Transurethral resection of the prostate (TURP) is a broadly performed procedure for relieving prostate obstruction to improve lower urinary tract symptom (LUTS). However, many patients persistently have LUTS and need continual medication after TURP. We conducted this study to investigate whether the resected prostate weight is a predictive factor for continual medication after TURP. METHODS The subset of the National Health Insurance Research Database (NHIRD) of Taiwan contains data of all medical benefit claims and covers most Taiwan populations. We included all patients receiving TURP from 2006 to 2009. Patients with a diagnosis of prostate cancer were excluded. All patients were followed for a minimal of 6 months. Since the claim code was different according to the resected prostate weight, we subdivided the patients into three subgroups: small (< 15 grams), medium (15∼50 grams), and large (> 50 grams). Medication with α blocker, antimuscarinics and bethanechol at 3 and 6 months after TURP was recorded. The medication must be more than 14 days. RESULTS Among the total population of 22.8 millions, 33905 patients received TURP. The patient's number of each groups were 14511 (42.8%) in small group, 16487 (48.6%) in medium group, and 2907 (8.6%) in large group. The patientsía number of α blocker at 3 and 6 months after TURP in each subgroup (small, medium, large) were 5312 (36.6%), 4249 (25.8%), 590 (20.3%) and 4623 (31.9%), 3617 (21.9%), 507 (17.4%), respectively. The patients' number of antimuscarinic drug at 3 and 6 months after TURP in each subgroup were 3368 (23.2%), 2886 (17.5%), 442 (15.2%) and 2679 (18.5%), 2135 (13.0%), 309 (10.6%). The patients' number of bethanechol at 3 and 6 months after TURP in each subgroup were 1918(13.2%), 1304 (7.9%), 163 (5.6%) and 1549 (10.7%), 981 (6.0%), 128 (4.4%). Relative risk of continual medication at 3 and 6 months after TURP were detailed in the table 1. In the table, smaller group revealed higher risk to continue medication of α blocker, antimuscarinics or bethanechol than larger one. CONCLUSIONS This study found that a smaller prostate could be a predictive factor for continual medication after TURP. It's necessary to verify the need for TURP for patients with a smaller prostate. Table 1. Relative risk of continual pharmacotherapy after TURP by using Logistic Regression model⁎ 3 months after TURP 6 months after TURP Adjusted OR 95% CI p value Adjusted OR 95% CI p value alpha blocker Small v.s. Large 2.3 2.0-2.5 < 0.001 2.2 2.0-2.5 < 0.001 Medium v.s. Large 1.4 1.2-1.5 < 0.001 1.3 1.2-1.5 0.002 Antimuscarinics Small v.s. Large 1.7 1.6-1.9 < 0.001 1.9 1.7-2.2 < 0.001 Medium v.s. Large 1.2 1.1-1.3 0.001 1.3 1.1-1.4 < 0.001 Bethanechol Small v.s. Large 2.5 2.1-3.0 < 0.001 2.6 2.1-3.1 < 0.001 Medium v.s. Large 1.4 1.2-1.7 < 0.001 1.4 1.1-1.7 0.001 ⁎ Adjusted with demography Factors: age, urbanized level, geographic location. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e567-e568 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Chih Chieh Lin Taipei, Taiwan More articles by this author Alex Tong Long Lin Taipei, Taiwan More articles by this author Hsiao Jen Chung Taipei, Taiwan More articles by this author Eric Yi Hsiu Huang Taipei, Taiwan More articles by this author Kuang Kuo Chen Taipei, Taiwan More articles by this author Tzeng Zi Chen Taipei, Taiwan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...